Use of “intracrine androgen signaling signature'' to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). The effect of changes in PSA kinetics on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results